Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

by Ysios Capital

Mineralys Therapeutics today announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease (CKD), ...

Read more

La nueva terapia celular, al rescate de la reparación de tejidos

by Peaches Biotech

Se destacan algunos párrafos que muestran lo que están en vía de aportar a las terapias celulares y el status de su proyecto PRS ®, biomedicamento inmunomodulador y antiinflamatorio

Read more

ORYZON reports financial results and corporate updates for half-year ending June 30, 2023

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the hal...

Read more

Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reports that full patient recruitment ...

Read more

Nature Medicine Publishes Discovery of New Pharmacological Class by Aelis Farma, Phase 2a Study of First Drug Candidate for Cannabis Use Disorder

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

Aelis Farma announced publication of a series of studies describing a new pharmacological class, cannabinoid receptor 1 signaling-specific inhibitors (CB1-SSi), and its first drug candidate, AEF0117, ...

Read more

VHIO spin-off Peptomyc receives approval to initiate its Phase Ib trial testing Omomyc in patients with metastatic pancreatic cancer

by VHIO

Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor Omomyc (OMO-103) with standard of care in metastatic pancreatic...

Read more

Un nuevo fármaco neuroprotector muestra buenos resultados preliminares para el ictus isquémico

by Hospital Universitari de Bellvitge

Han publicado los resultados positivos del ensayo clínico APRIL de Fase 1b/2a de aptaTargets, que ha evaluado la seguridad y eficacia del innovador fármaco neuroprotector ApTOLL en combinación con ...

Read more

La Organización Mundial de la Salud incluye la polipíldora cardiovascular desarrollada por el CNIC y Ferrer en la lista de medicamentos esenciales

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

La polipíldora cardiovascular desarrollada por el Centro Nacional de Investigaciones Cardiovasculares (CNIC) y Ferrer, acaba de ser incluida por la Organización Mundial de la Salud (OMS) en la lista...

Read more

Vall d'Hebron leads an international phase III clinical trial demonstrating the efficacy of atogepant, an oral drug for the prevention of chronic migraine

by Vall d’Hebron

Atogepant is the first oral drug that can be useful for patients with chronic migraine, which makes it easier to access, provides flexibility in drug administration and is easier to store, since injec...

Read more

First clinical trial of a treatment that attacks lung cancer and brain metastasis at the same time

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

A study has shown that the combination of chemotherapy and atezolizumab, an antibody that stimulates the immune system’s ability to attack cancer cells, is an effective treatment for lung cancer pat...

Read more

AbilityPharma will secure 7 million euros with a collective investment campaign in Capital Cell of up to 2 million to finance itself until the results of its international phase 2b study in pancreatic cancer

by Ability Pharma

The Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes a collective investment campaign of up to 2 million on the Capital C...

Read more

Vall d'Hebron has participated in one of the clinical trials that have enabled the approval of the first specific pill for postpartum depression in the United States

by Vall d’Hebron

The United States has approved Zurzuvae, the first oral treatment specifically for postpartum depression, based on allopregnanolone, a neurosteroid created by the female sex hormone progesterone.

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

The Dhx15 gene could be a target for dia...

by Fundació Clínic per a la Recerca Biomèdica

A study by the Clínic-IDIBAPS shows that silencing this gene reduces ...

Photos Stream